Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

NCT06416436 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Impasse during contract negotitations

Conditions

Solid Tumor

Interventions

DRUG: Atezolizumab
RADIATION: Stereotactic Ablative Radiotherapy (SBRT)

Sponsor

University of Kansas Medical Center